Trou­bled aTyr ax­es 30% of its staff as it wipes a pre­clin­i­cal slate clean

Faced with dis­ap­point­ing re­sults from its lat­est pre­clin­i­cal pro­gram, aTyr Phar­ma is cut­ting the de­vel­op­ment short and let­ting go around 30% of its staff.

The San Diego-based biotech $LIFE has dis­card­ed IND plans for what would have been its third clin­i­cal pro­gram, dubbed Project OR­CA. In a state­ment, it said the re­struc­tur­ing and oth­er cost-sav­ing mea­sures are aimed at get­ting its sec­ond as­set, ATYR1923, on track for PhII de­vel­op­ment.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN